After withdrawal, GSK touts another Blenrep combo win as …
WEBMar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBGlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in two phase III …
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression …
WEBJun 3, 2024 · On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus...
GSK to stop selling blood cancer drug Blenrep in United States
WEBNov 22, 2022 · GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business.
Blenrep combination reduced the risk of disease progression or …
WEBJun 2, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory ...
GSK provides an update on Blenrep (belantamab mafodotin …
WEBNov 22, 2022 · GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA).
GSK provides an update on Blenrep (belantamab mafodotin-blmf) …
WEBNov 22, 2022 · BLENREP caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes. Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms.
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBNov 27, 2023 · GSK Announces Positive Results in a Phase III Trial of Blenrep. On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma.
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · The combination of Blenrep with Takeda’s Velcade and the steroid dexamethasone (Vd) significantly cut the risk of progression or death by 59% compared with Johnson & Johnson’s Darzalex and Vd in...